The global cell lysis & disruption market is expanding at a registered CAGR of around 6.7% from 2021 to 2030 and to reach valuation US$ 6.17 billion by 2028 from valued at US$ 3.93 billion in 2021.
The global cell lysis & disruption market is expanding at a registered CAGR of around 6.7% from 2021 to 2030 and to reach valuation US$ 6.17 billion by 2028 from valued at US$ 3.93 billion in 2021.
Growth Factors
Cell lysis and disruption is significantly used in the diagnosis of pathogens, diagnosis of immunoassays, understanding the structure of proteins and its functions, and mRNA transcriptome determination in the diagnostic labs. The cell lysis and disruption technology is extensively used for the diagnosis of cancer in patients. Therefore, the rising prevalence of cancer among the population owing to various factors such as tobacco consumption, rising prevalence of smoking, and increased consumption of processed food is expected to drive the demand for the diagnosis of cancer, thereby fueling the demand for the cell lysis and disruption technology. According to GLOBOCAN report by the International Agency for Research on Cancer, approximately 19.3 million new cancer cases and around 10 million cancer deaths were recorded in 2020 around the globe. It is also estimated that the new cancer cases will rise by 47% from 2020 to 2040. Thus, the demand for the cell lysis and disruption is expected to grow significantly in the forthcoming years.
Get the sample copy of report@ https://www.precedenceresearch.com/sample/1292
Report Highlights:
- Based on the product, the reagents segment dominated the market in 2020. The increased investments pertaining to the cell based research works, rising prevalence of chronic diseases, and huge consumption of the reagents in the diagnostic labs are the major factors that has driven the growth of the reagents segment. The surging adoption of the enzymes and detergent reagents is projected to further fuel the growth of the market.
- Based on the cell type, the mammalian cells was the dominating segment with 46% of the market share in 2020. The extensive consumption of the mammalian cells in the biopharmaceutical industry for the production of therapeutic proteins, vaccines, and gene therapies has augmented the growth of the mammalian cell segment. The surging investments on the research on cancer pertaining to the use of mammalian cells is further driving the segment’s growth.
- By application, the isolation segment garnered a market share of 33% and dominated the global cell lysis and disruption market in 2020. The rising application of the isolation in western blotting, proteomics, and immune-precipitation has led to the dominance of the isolation segment in the global market.
- On the basis of end use, the pharma & biotechnology companies segment dominated the cell lysis market in 2020. The wide deployment of the cell lysis and disruption technology by the biopharmaceutical companies for conducting studies about molecular biology and bioprocesses has significantly contributed to the growth of the market.
- North America led the global cell lysis and disruption market, garnering about 40% of the market share in 2020. The presence of numerous top biopharmaceutical companies in the region and rising investments by them in the research and development of the various diagnostics and therapies has augmented the growth of the North America cell lysis & disruption market. The rapid growth of the biopharmaceutical industry in North America is expected to significantly boost the market growth in the foreseeable future.
- The rising investments by the top biopharmaceutical companies for the expansion in Asia Pacific region is expected to foster the growth of the Asia Pacific cell lysis and disruption market and hence, this region is estimated to be the fastest-growing market during the forecast period. Asia Pacific is the home to several top biopharmaceutical companies and the growing government initiatives to support the growth of the pharmaceutical and healthcare sector will positively impact the market growth.
Ask here for customization@ https://www.precedenceresearch.com/customization/1292
Future of Cell Lysis & Disruption Market
The growing prevalence of various chronic diseases like cancer and the surging adoption of the mammalian cells for lysis and disruption owing to its low costs is expected to drive the growth of the market in the upcoming future. Furthermore, the adoption of the 3D mammalian cell culture systems is estimated to positively impact the market.
COVID-19 Impact Analysis:
- The downstream processing application witnessed an increased demand for the development of COVID-19 vaccines, which supported the growth of the cell lysis and disruption market during the pandemic.
- The increased investments in the research and development for the development of diagnosis and vaccines for the treatment of COVID-19 patients positively impacted the market growth.
Browse more related reports@ https://www.precedenceresearch.com/industry/healthcare
Key Developments in the Marketplace:
In January 2021, Thermo Fisher Scientific acquired Henogen S.A., a part of Novasep, to enhance its production capacities of cell therapies, cell lysis, gene therapies, and vaccines.
Segments Covered in the Report
By Product
- Instruments
- Reagents
By Cell Type
- Bacteria Cells
- Mammalian Cells
- Plant Cells
- Yeast/Fungi/Algae
By Application
- Cell Organelle Isolation
- Protein Isolation
- Downstream Processing
- Nucleic Acid Isolation
By End Use
- Hospitals and Diagnostic Laboratories
- Cell Banks
- Academic and Research Institutions
- Pharma & Biotechnology Companies
By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- MEA
Click Here to View Full Report Table of Contents
Buy this Research Report@ https://www.precedenceresearch.com/checkout/1292
You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333